Secukinumab in the treatment of moderate to severe hidradenitis suppurativa: Results of an open-label trial
J Am Acad Dermatol
.
2020 Jun;82(6):1524-1526.
doi: 10.1016/j.jaad.2020.02.005.
Epub 2020 Feb 7.
Authors
Rachel G Casseres
1
,
Lisa Prussick
1
,
Pedro Zancanaro
2
,
Brooke Rothstein
2
,
Deep Joshipura
2
,
Ami Saraiya
2
,
Yana Turkowski
2
,
Shiu Chung Au
2
,
Abdulaziz Alomran
2
,
Rana Abdat
2
,
Minawaer Abudu
2
,
Courtney Kachuk
2
,
Nicole Dumont
2
,
Alice B Gottlieb
3
,
David Rosmarin
4
Affiliations
1
Tufts Medical Center, Department of Dermatology, Boston, Massachusetts; Tufts University School of Medicine, Boston, Massachusetts.
2
Tufts Medical Center, Department of Dermatology, Boston, Massachusetts.
3
Icahn School of Medicine at Mount Sinai, Department of Dermatology, New York, New York.
4
Tufts Medical Center, Department of Dermatology, Boston, Massachusetts. Electronic address: Drosmarin@tuftsmedicalcenter.org.
PMID:
32044410
DOI:
10.1016/j.jaad.2020.02.005
No abstract available
Publication types
Clinical Trial
Letter
MeSH terms
Adult
Antibodies, Monoclonal, Humanized / therapeutic use*
Female
Hidradenitis Suppurativa / drug therapy*
Humans
Male
Middle Aged
Severity of Illness Index
Substances
Antibodies, Monoclonal, Humanized
secukinumab